GLAXF GSK plc

NEUTRAL Impact: 3/10 6-K
Horizon immediate Filed Apr 10, 2026 Processed 2mo ago SEC 0001654954-26-003401
Notable filing: 6-K
Latest settled — T+20d ⚠ clustered
GLAXF ▼ -13.64% at T+20d
NEUTRAL call ✗ call lost -13.64% · α vs SPY -22.17% · entry $29.25 → $25.26
Next anchor: T+60d in 27d
Last close $24.66 (close Jun 8) · -15.69% from $29.25 entry
Entry anchored
Apr 10, 2026
via day open
T+1d
0.00%
call 0.00% · α -0.98%
$29.25
settled 8w ago
T+5d
+0.85%
call +0.85% · α -3.65%
$29.50
settled 8w ago
T+20d
-13.64%
call -13.64% · α -22.17%
$25.26
settled 5w ago
T+60d
call — · α —
in 27d

Price Chart

Loading chart...

Executive Summary

GSK executives and associated persons acquired ordinary shares through dividend reinvestment under the company's Share Reward Plan on April 9, 2026. These are routine, non-discretionary transactions reflecting standard compensation plan activity, not new insider buying signals.

Actionable Insight

No trading action warranted. These filings reflect standard, pre-arranged dividend reinvestments, not strategic insider buying. Monitor for larger discretionary purchases or changes in sentiment.

Key Facts

  • Multiple PDMRs (Persons Discharging Managerial Responsibilities) and PCAs (Persons Closely Associated) acquired GSK ordinary shares on April 9, 2026.
  • Transactions were executed via dividend reinvestment under the Company's Share Reward Plan, a standard, non-discretionary process.
  • CEO Luke Miels acquired 2 shares at £21.3387; other executives acquired between 5 and 67 shares at the same price.
  • Victoria Whyte (SVP & Company Secretary) and her associated person Iain Whyte made separate purchases at £21.5039, totaling 1,214 shares.
  • All transactions occurred on the London Stock Exchange (XLON).

Financial Impact

Minimal. Total shares acquired by insiders are small in volume and value, representing routine plan activity rather than material investment.

insider ownership

Risk Factors

  • Misinterpretation of routine transactions as bullish sentiment could lead to incorrect positioning.
  • Future changes in insider transaction patterns (e.g., shift from reinvestment to open market buys) could signal changing confidence.

Market Snapshot

Exchange
OTC
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001654954-26-003401
Document: 0001654954-26-003401-index-headers.html0001654954-26-003401
Document: 0001654954-26-003401-index.html0001654954-26-003401
Document: 0001654954-26-003401.txt0001654954-26-003401
50 reports for GLAXF
Performance horizon
42% Hit rate 5 of 12 directional calls best @ T+5▲ +7.60%Apr 1, 2026
Filters
Rows
Reports for GLAXF — sortable, filterable
Type Now
Jun 9, 2026
today
6-K
NEUTRAL ★ 1/10
awaiting T+5
Jun 9, 2026
today
6-K
BULLISH ★ 7/10
awaiting T+5
Jun 1, 2026
8d ago
6-K
NEUTRAL ★ 1/10
$24.25 $24.66▲ +1.69%▲ +4.44%$24.66 (+1.69%)
Jun 1, 2026
8d ago
6-K
NEUTRAL ★ 2/10
$24.25 $24.66▲ +1.69%▲ +4.44%$24.66 (+1.69%)
May 28, 2026
12d ago
6-K
BULLISH ★ 7/10
$24.58 $24.66▲ +0.33%▲ +0.01%$24.66 (+0.33%)
May 27, 2026
13d ago
6-K
NEUTRAL ★ 1/10
$25.57 $23.94▼ −6.37%▼ −7.58%$24.66 (−3.56%)
May 26, 2026
14d ago
6-K
NEUTRAL ★ 1/10
$25.50 $24.25▼ −4.90%▼ −5.99%$24.66 (−3.29%)
May 26, 2026
14d ago
6-K
NEUTRAL ★ 2/10
$25.50 $24.25▼ −4.90%▼ −5.99%$24.66 (−3.29%)
May 22, 2026
18d ago
6-K
NEUTRAL ★ 2/10
$26.00 $24.25▼ −6.73%▼ −8.39%$24.66 (−5.15%)
May 20, 2026
20d ago
6-K
NEUTRAL ★ 2/10
$25.70 $25.57▼ −0.51%▼ −1.74%$24.66 (−4.05%)
Showing 10 of 50

US Market Status

Market Closed — Opens in 7h 14m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access